{"publication_id":"b3041d87-87dd-46e9-a8ea-5a13c317c885","screening":{"identified":30,"screened":30,"excluded":0,"included":30,"included_or_retained":30,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"30 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["Across outcome classes, cross-study disagreements were identified, with null findings dominating contextual and safety outcomes while context-specific signals concentrated in preclinical longevity and immune biomarker domains.","The current evidence supports mechanistic plausibility for rapamycin's geroprotective effects but falls short of establishing clinical biomarker efficacy, as human randomized trials show largely null or mixed results on conventional healthspan endpoints.","18 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=12, positive=2, unclear=2. Directness coding: direct=1, indirect=10, mechanistic=7.","2 included sources were assigned to this outcome class. Directional coding: mixed=1, null=1. Directness coding: indirect=1, mechanistic=1.","Several outcome domains in the corpus rest on single-study evidence, which precludes internal replication and inflates the risk that observed effects are idiosyncratic to a particular design, population, or analytic approach. Likewise, airway inflammation and emphysema attenuation were demonstrated exclusively in Tian 2026 using ozone-exposed mice treated with intraperitoneal rapamycin at 0.6 mg/kg, and cardiac function preservation in autoimmune myocarditis was reported only by Zhuang 2025, who showed rapamycin reprogrammed Cxcl9+ macrophages via the mTORC1–C/EBPβ–OSM axis. Cardiac proteomic remodeling was studied only by Dai 2014, who used deuterated-leucine labeling over 10 weeks of rapamycin exposure, while the longevity-in-Drosophila pathway was examined solely by Bjedov 2010. The ME/CFS fatigue endpoint was explored in only Ruan 2025, a pilot study administering 6 mg/week rapamycin with symptom assessments at days 30, 60, and 90. In each of these cases, a single source cannot establish whether the effect is robust across independent laboratories, species, or populations. This single-trial limitation is not confined to minor outcomes: the cross-study disagreement map documents severity-3 or severity-4 disagreements for the contextual other outcome class across 161 non-orthogonal pairs, yet many of these tensions involve one or both arms supported by only a single study, making adjudication between conflicting signals impossible within the current corpus.","The population base of the curated trials narrows external validity in several ways that cannot be resolved by pooling alone. Preclinical sources — including Bitto 2016 (middle-aged mice), Harrison 2009 (genetically heterogeneous mice), Miller 2014 (dose-response in mice), Tian 2026 (ozone-exposed mice), and Pell 2026 (female mice with early-life seizures) — collectively dominate the longevity and mechanistic outcome classes, yet interspecies translation of mTOR inhibition remains uncertain because murine mTOR signaling kinetics, rapamycin pharmacokinetics, and lifespan architecture differ from those of humans. Stanfield 2026 tested once-weekly sirolimus at 6 mg in older adults already engaged in a 13-week exercise program, which introduces a selection bias toward motivated, physically active participants who may not represent the sedentary majority at risk for age-related decline. No study in the corpus enrolled pregnant individuals, persons with severe renal or hepatic impairment, or immunocompromised populations such as organ-transplant recipients on concurrent immunosuppression, leaving safety and efficacy in these vulnerable groups entirely uncharacterized. Consequently, the synthesis conclusions apply most directly to middle-aged to older, relatively healthy adults or to murine models, and extrapolation beyond these groups requires assumptions that the present evidence cannot anchor.","The endpoint scope of the corpus is heavily weighted toward mechanistic, surrogate, and contextual outcomes rather than clinically meaningful endpoints validated against hard disease outcomes, which introduces a translation gap that should be made explicit. No source in the curated set measured incident type 2 diabetes, fracture incidence, hospitalization for heart failure, or time-to-progression of any cancer as a primary endpoint; the cardiometabolic class is represented only by Zhang 2021 and Su 2025, both mechanistic studies examining BCRP-mediated drug resistance and MAGEA3 biomarkers rather than patient-centered outcomes. Rosario 2023 investigated rapamycin's attenuation of PI3K signaling in human ovarian cortex in vitro, providing mechanistic evidence for fertility preservation, but no clinical trial in the corpus reported on pregnancy rates, ovarian reserve markers such as anti-Müllerian hormone trajectory, or time-to-conception in women receiving rapamycin. A broader methodological concern is that several sources relied on surrogate endpoints whose clinical validity for the aging context is unestablished: as noted in the general methodological literature (Ioannidis 2005), surrogate associations do not guarantee hard-outcome validity. Hallmarks such as senescence-associated secretory phenotype suppression (Wang 2017) and mTOR-pathway phosphorylation changes (Hibbert 2026) are biologically informative but remain at least one mechanistic step removed from endpoints that patients or clinicians would recognize as meaningful improvements in survival, disability, or quality of life. Until the evidence base includes trials that bridge from these mechanistic surrogates to validated clinical endpoints, the risk-benefit calculus for off-label rapamycin use in healthy adults remains fundamentally unresolved.","For rapamycin biomarker effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 30 curated reference papers, the evidence base for Rapamycin Biomarker Effects shows a context-dependent profile. Positive signals appear in: contextual other, immune inflammation. Negative signals appear in: contextual other. Null findings dominate: contextual other, safety comorbidity. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Rapamycin Biomarker Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."]}